New shot aims to keep liver cancer away after treatment
NCT ID NCT06526338
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study tests a single injection of IP-001 given right after surgery or ablation for liver cancer (hepatocellular carcinoma). The goal is to see if it can safely delay or prevent the cancer from returning. About 126 adults with high-risk liver cancer will take part and be followed with regular scans for several years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.